NCT03824080 is a Phase 2 clinical trial of Bemcentinib in Acute Myeloid Leukemia, sponsored by GWT-TUD GmbH.

Who is sponsoring NCT03824080?

NCT03824080 is sponsored by GWT-TUD GmbH.

What drugs are being tested in NCT03824080?

Interventions in NCT03824080: Bemcentinib.

What condition does NCT03824080 study?

NCT03824080 studies Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome, Low-risk Myelodysplastic Syndrome.

Is NCT03824080 still recruiting?

NCT03824080 is currently completed. Last updated 21 December 2021.

Last reviewed 2021-12-21 · How we verify

NCT03824080

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

Completed Phase 2 Last updated 21 December 2021

What this trial tests

Phase 2 trial testing Bemcentinib in Acute Myeloid Leukemia in 45 participants. Completed in 8 June 2021.

Timeline

20 December 2018

Primary endpoint
13 July 2020

8 June 2021

Quick facts

Lead sponsor	GWT-TUD GmbH
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	20 December 2018
Primary completion	13 July 2020
Estimated completion	8 June 2021
Sites	8 locations across France, Netherlands, Germany

Drugs / interventions tested

Bemcentinib — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
High-risk Myelodysplastic Syndrome — all drugs for High-risk Myelodysplastic Syndrome →
Low-risk Myelodysplastic Syndrome — all drugs for Low-risk Myelodysplastic Syndrome →

Sponsor

GWT-TUD GmbH — full company profile →

Who can join

18 and older, any sex, with Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, single-arm multicenter, phase II study. The primary objective is to assess the efficacy of bemcentinib (BGB324) a highly selective inhibitor of the AXL receptor tyrosine kinase for the treatment of AML and MDS patients failing or being refractory to first line hypomethylating agent (HMA) treatment. Furthermore, safety, disease progression, treatment failure will be assessed. A total of 43 patients will be included in the trial.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C, Wei Y, Wei X. · · 2019 · cited 398× · PMID 31684958 · DOI 10.1186/s12943-019-1090-3
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets.
Di X, Gao X, Peng L, Ai J, et al · · 2023 · cited 358× · PMID 37518181 · DOI 10.1038/s41392-023-01501-9
Drugging the efferocytosis process: concepts and opportunities.
Mehrotra P, Ravichandran KS. · · 2022 · cited 319× · PMID 35650427 · DOI 10.1038/s41573-022-00470-y
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.
Carter JL, Hege K, Yang J, Kalpage HA, et al · · 2020 · cited 148× · PMID 33335095 · DOI 10.1038/s41392-020-00361-x
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, et al · · 2024 · cited 133× · PMID 39138146 · DOI 10.1038/s41392-024-01899-w
Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB, Domaica CI, Zwirner NW. · · 2021 · cited 110× · PMID 34394116 · DOI 10.3389/fimmu.2021.713158
Current challenges and unmet medical needs in myelodysplastic syndromes.
Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T. · · 2021 · cited 67× · PMID 34045662 · DOI 10.1038/s41375-021-01265-7
Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.
Tanaka M, Siemann DW. · · 2021 · cited 60× · PMID 34576116 · DOI 10.3390/ijms22189953

Verify or expand the search:

Other trials of Bemcentinib

Trials testing the same drug.

NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting
NCT05469178 — A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell · Phase 1, PHASE2 · terminated
NCT06469138 — A Study to Investigate 14C-bemcentinib in Healthy Male Subjects · Phase 1 · completed
NCT04890509 — A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients · Phase 2 · completed
NCT03649321 — Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer · Phase 1, PHASE2 · terminated

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other GWT-TUD GmbH trials

Trials by the same sponsor.

NCT05181592 — Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. · Phase 3 · active not recruiting
NCT04833114 — Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line · Phase 3 · active not recruiting
NCT04188639 — Emicizumab in Acquired Hemophilia A · Phase 2 · completed
NCT04257448 — Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From · Phase 1, PHASE2 · completed
NCT04121507 — ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03824080 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GWT-TUD GmbH
Last refreshed: 21 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03824080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing